



## Tempest Therapeutics to Present at Two Investor Conferences in August

July 31, 2020

**South San Francisco, CA – July 31, 2020** - Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that management will present at the following investor conferences in August 2020:

- 10th Annual William Blair BioTech Focus Conference on Tuesday, August 4<sup>th</sup> at 1:35 pm ET
- LifeSci Partners: Private Summer Symposium on Wednesday, August 5<sup>th</sup> at 1:30 pm ET

To access the live webcasts and subsequent archived recordings of these presentations, please visit the Tempest website at <https://www.tempestx.com/#investors>.

### About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both precision and immune-mediated mechanisms with the potential to target a wide range of tumors. The company's two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPAR $\alpha$  and EP2/4, respectively. Both TPST-1120 and TPST-1495 are progressing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an inhibitor of TREX-1, an exonuclease highly expressed in tumors that suppresses both STING and tumor immunity, to activate STING selectively in tumors via a systemically-delivered small molecule. Tempest is headquartered in South San Francisco and supported by notable healthcare investors. More information about Tempest can be found on the company's website at [www.tempestx.com](http://www.tempestx.com).

### Corporate Communications Contacts

Sylvia Wheeler  
[swheeler@wheelhousesa.com](mailto:swheeler@wheelhousesa.com)

Alex Santos  
[asantos@wheelhousesa.com](mailto:asantos@wheelhousesa.com)